Regulatory approval of cancer risk-reducing (chemopreventive) drugs

Moving what we have learned into the clinic

Frank L. Meyskens, Gregory A. Curt, Dean E. Brenner, Gary Gordon, Ronald B. Herberman, Olivera Finn, Gary J. Kelloff, Samir N. Khleif, Caroline C. Sigman, Eva Szabo

Research output: Contribution to journalComment/debate

37 Citations (Scopus)

Abstract

This article endeavors to clarify the current requirements and status of regulatory approval for chemoprevention (risk reduction) drugs and discusses possible improvements to the regulatory pathway for chemoprevention. Covering a wide range of topics in as much depth as space allows, this report is written in a style to facilitate the understanding of nonscientists and to serve as a framework for informing the directions of experts engaged more deeply with this issue. Key topics we cover here are as follows: a history of definitive cancer chemoprevention trials and their influence on the evolution of regulatory assessments; a brief review of the long-standing success of pharmacologic risk reduction of cardiovascular diseases and its relevance to approval for cancer risk reduction drugs; the use and limitations of biomarkers for developing and the approval of cancer risk reduction drugs; the identification of individuals at a high (er) risk for cancer and who are appropriate candidates for risk reduction drugs; business models that should incentivize pharmaceutical industry investment in cancer risk reduction; a summary of scientific and institutional barriers to development of cancer risk reduction drugs; and a summary of major recommendations that should help facilitate the pathway to regulatory approval for pharmacologic cancer risk reduction drugs.

Original languageEnglish (US)
Pages (from-to)311-323
Number of pages13
JournalCancer Prevention Research
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Risk Reduction Behavior
Pharmaceutical Preparations
Neoplasms
Chemoprevention
Drug Industry
Cardiovascular Diseases
Biomarkers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Meyskens, F. L., Curt, G. A., Brenner, D. E., Gordon, G., Herberman, R. B., Finn, O., ... Szabo, E. (2011). Regulatory approval of cancer risk-reducing (chemopreventive) drugs: Moving what we have learned into the clinic. Cancer Prevention Research, 4(3), 311-323. https://doi.org/10.1158/1940-6207.CAPR-09-0014

Regulatory approval of cancer risk-reducing (chemopreventive) drugs : Moving what we have learned into the clinic. / Meyskens, Frank L.; Curt, Gregory A.; Brenner, Dean E.; Gordon, Gary; Herberman, Ronald B.; Finn, Olivera; Kelloff, Gary J.; Khleif, Samir N.; Sigman, Caroline C.; Szabo, Eva.

In: Cancer Prevention Research, Vol. 4, No. 3, 01.03.2011, p. 311-323.

Research output: Contribution to journalComment/debate

Meyskens, FL, Curt, GA, Brenner, DE, Gordon, G, Herberman, RB, Finn, O, Kelloff, GJ, Khleif, SN, Sigman, CC & Szabo, E 2011, 'Regulatory approval of cancer risk-reducing (chemopreventive) drugs: Moving what we have learned into the clinic', Cancer Prevention Research, vol. 4, no. 3, pp. 311-323. https://doi.org/10.1158/1940-6207.CAPR-09-0014
Meyskens, Frank L. ; Curt, Gregory A. ; Brenner, Dean E. ; Gordon, Gary ; Herberman, Ronald B. ; Finn, Olivera ; Kelloff, Gary J. ; Khleif, Samir N. ; Sigman, Caroline C. ; Szabo, Eva. / Regulatory approval of cancer risk-reducing (chemopreventive) drugs : Moving what we have learned into the clinic. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 3. pp. 311-323.
@article{2d1abab07575456689e68be39e9cbfb0,
title = "Regulatory approval of cancer risk-reducing (chemopreventive) drugs: Moving what we have learned into the clinic",
abstract = "This article endeavors to clarify the current requirements and status of regulatory approval for chemoprevention (risk reduction) drugs and discusses possible improvements to the regulatory pathway for chemoprevention. Covering a wide range of topics in as much depth as space allows, this report is written in a style to facilitate the understanding of nonscientists and to serve as a framework for informing the directions of experts engaged more deeply with this issue. Key topics we cover here are as follows: a history of definitive cancer chemoprevention trials and their influence on the evolution of regulatory assessments; a brief review of the long-standing success of pharmacologic risk reduction of cardiovascular diseases and its relevance to approval for cancer risk reduction drugs; the use and limitations of biomarkers for developing and the approval of cancer risk reduction drugs; the identification of individuals at a high (er) risk for cancer and who are appropriate candidates for risk reduction drugs; business models that should incentivize pharmaceutical industry investment in cancer risk reduction; a summary of scientific and institutional barriers to development of cancer risk reduction drugs; and a summary of major recommendations that should help facilitate the pathway to regulatory approval for pharmacologic cancer risk reduction drugs.",
author = "Meyskens, {Frank L.} and Curt, {Gregory A.} and Brenner, {Dean E.} and Gary Gordon and Herberman, {Ronald B.} and Olivera Finn and Kelloff, {Gary J.} and Khleif, {Samir N.} and Sigman, {Caroline C.} and Eva Szabo",
year = "2011",
month = "3",
day = "1",
doi = "10.1158/1940-6207.CAPR-09-0014",
language = "English (US)",
volume = "4",
pages = "311--323",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Regulatory approval of cancer risk-reducing (chemopreventive) drugs

T2 - Moving what we have learned into the clinic

AU - Meyskens, Frank L.

AU - Curt, Gregory A.

AU - Brenner, Dean E.

AU - Gordon, Gary

AU - Herberman, Ronald B.

AU - Finn, Olivera

AU - Kelloff, Gary J.

AU - Khleif, Samir N.

AU - Sigman, Caroline C.

AU - Szabo, Eva

PY - 2011/3/1

Y1 - 2011/3/1

N2 - This article endeavors to clarify the current requirements and status of regulatory approval for chemoprevention (risk reduction) drugs and discusses possible improvements to the regulatory pathway for chemoprevention. Covering a wide range of topics in as much depth as space allows, this report is written in a style to facilitate the understanding of nonscientists and to serve as a framework for informing the directions of experts engaged more deeply with this issue. Key topics we cover here are as follows: a history of definitive cancer chemoprevention trials and their influence on the evolution of regulatory assessments; a brief review of the long-standing success of pharmacologic risk reduction of cardiovascular diseases and its relevance to approval for cancer risk reduction drugs; the use and limitations of biomarkers for developing and the approval of cancer risk reduction drugs; the identification of individuals at a high (er) risk for cancer and who are appropriate candidates for risk reduction drugs; business models that should incentivize pharmaceutical industry investment in cancer risk reduction; a summary of scientific and institutional barriers to development of cancer risk reduction drugs; and a summary of major recommendations that should help facilitate the pathway to regulatory approval for pharmacologic cancer risk reduction drugs.

AB - This article endeavors to clarify the current requirements and status of regulatory approval for chemoprevention (risk reduction) drugs and discusses possible improvements to the regulatory pathway for chemoprevention. Covering a wide range of topics in as much depth as space allows, this report is written in a style to facilitate the understanding of nonscientists and to serve as a framework for informing the directions of experts engaged more deeply with this issue. Key topics we cover here are as follows: a history of definitive cancer chemoprevention trials and their influence on the evolution of regulatory assessments; a brief review of the long-standing success of pharmacologic risk reduction of cardiovascular diseases and its relevance to approval for cancer risk reduction drugs; the use and limitations of biomarkers for developing and the approval of cancer risk reduction drugs; the identification of individuals at a high (er) risk for cancer and who are appropriate candidates for risk reduction drugs; business models that should incentivize pharmaceutical industry investment in cancer risk reduction; a summary of scientific and institutional barriers to development of cancer risk reduction drugs; and a summary of major recommendations that should help facilitate the pathway to regulatory approval for pharmacologic cancer risk reduction drugs.

UR - http://www.scopus.com/inward/record.url?scp=79955466351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955466351&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-09-0014

DO - 10.1158/1940-6207.CAPR-09-0014

M3 - Comment/debate

VL - 4

SP - 311

EP - 323

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 3

ER -